Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders

References

• Grundy SM, Benjamin U, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.
   PubMed Web of Science ®Google Scholar
• Fruchart J-C, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008;5:319–35.
   Google Scholar
• Cornier M-A, Despres J-P, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, Towfighi A, Poirier P. on behalf of the American Heart Association Obesity Committee of the Council on Nutrition; Physical Activity and Metabolism; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: a Scientific Statement from the American Heart Association. Circulation 2011;124:1996–2019.
   Google Scholar
• De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L. Normal-weight obese syndrome: early inflammation?Am J Clin Nutr 2007;85:40–5.
   PubMed Web of Science ®Google Scholar
• Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010;31:737–46.
   PubMed Web of Science ®Google Scholar
• Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15:1897–903.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011; 60:499–512.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Bulur S, Uğur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010;142:72–9.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393–9.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ademoğlu E, Çelik E, Karagöz A, Örnek E. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013;61:27–33.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G. Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharmaceut Design 2013 Apr 2 [Epub]
   Google Scholar
• Wang J, Gong J, Li H, Niu D, Han A, Wu J, Zhang C. Lipoprotein(a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb 2012;19:81–9.
   PubMed Web of Science ®Google Scholar
• Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1–10.
   PubMed Web of Science ®Google Scholar
• Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182–90.
   PubMed Web of Science ®Google Scholar
• Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26:3160–7.
   Google Scholar
• Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd edn. Geneva: WHO, 1982, p. 124–7.
   Google Scholar
• Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non- insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996;335:1636–42.
   PubMedGoogle Scholar
• Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, Kambe H. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care 2009;32:424–6.
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, Sattar N, Zukowska- Szczechowska E, Dominiczak AF. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007; 71:816–21.
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Nath SD, Hanley AJG, Abboud HE, Gelfond JA, Haffner SM. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia 2009;52:1290–7.
   Google Scholar
• Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214–9.
   PubMed Web of Science ®Google Scholar
• Rule AD, Rodeheffer RJ, Larson TS, Burnett TS Jr, Cosio FG, Turner ST, Jacobsen ST. Limitation of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc 2006;81:1427–34.
   Google Scholar
• Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAF- acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004;177: 193–201.
   PubMed Web of Science ®Google Scholar
• Farsi A, Domeneghetti MP, Fedi S, Capanni M, Giusti B, Marcucci R, Giurlani L, Prisco D, Passaleva A, Gensini GF, Abbate R. High prevalence of anti-beta 2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999;30:93–8.
   PubMed Web of Science ®Google Scholar
• Worgall TS. Sphingolipids: major regulators of lipid metabolism. Curr Opin Clin Nutr Metab Care 2007;10:149–55.
   Google Scholar
• Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, Uchida K, Yajima J. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008;397:42–7.
   Google Scholar
• Haase CL, Tybjaerg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010;95:E500–10.
   PubMed Web of Science ®Google Scholar